Affiliation:
1. Department of Chemistry, GITAM University, Hyderabad Campus, Telangana, India.
2. Department of Chemistry, Krishna University, Machilipatnam, A.P., India.
Abstract
Ambrisentan, an endothelin receptor antagonist, is subjected to forced degradation under neutral hydrolytic conditions, leading to a potential unknown impurity. This neutral degradation product (DP) has been detected using reverse-phase ultra-performance liquid chromatography (UPLC), where it has eluted at 1.24 relative retention time to the Ambrisentan peak. DP was isolated using semi-preparative HPLC from the degradation mixture. Later, the structure of DP was elucidated using high-resolution mass spectrometry, 2D Nuclear magnetic resonance spectroscopy (NMR), and Fourier transformed infrared spectroscopy (FTIR) spectroscopic techniques and characterized as 2-(2,2- diphenylvinyloxy)-4,6-dimethylpyrimidine.
Subject
Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference16 articles.
1. Simonneau G, Galie N, Rubin L, et al. Clinical classification of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43: S5–12
2. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007 ; 131(6): 1917–28
3. Driscoll JA, Chakinala MM. Medical therapy for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy. 2008; 9(1): 65–81
4. WHO. The Global Alliance against Chronic Respiratory Diseases. Pulmonary hypertension [Accessed 2008 Jul 2]
5. Galié, N.; Barberá, J.A.; Frost, A.; Ghofrani, H.; Hoeper, M.M.; McLaughlin, V.; Peacock, A.; Simonneau, G.; Vachiery, J.; Grunig, E.; Oudiz, R.; Vonk-Noordegraaf, A.; White, R.; Blair,C.; Gillies, H.; Miller, K.; Harris, J.; Langley, J.; Rubin, L. Inicial use of ambrisentanplustadalafil in pulmonary arterial hypertension. N. Engl. J. Med., 2015, 373, 834-844